Cudarolimab

Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research[1].

Product Specifications

CAS Number

[2244739-29-3]

Product Name Alternative

IBI101

UNSPSC

12352203

Target

Orexin Receptor (OX Receptor)

Type

Inhibitory Antibodies

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cudarolimab.html

Purity

95.00

Solubility

10 mM in DMSO

Smiles

[Cudarolimab]

Molecular Weight

(145.94 kDa)

References & Citations

[1]Kuang Z, et al. Development and characterization of a novel anti-OX40 antibody for potent immune activation. Cancer Immunol Immunother. 2020 Jun;69 (6) :939-950.